VISTA.COMP — an engineered checkpoint receptor agonist that potently suppresses T cell–mediated immune responses-Reference-Cited by-同舟云学术

VISTA.COMP — an engineered checkpoint receptor agonist that potently suppresses T cell–mediated immune responses

Published:2017-09-21 Issue:18 Volume:2 Page:
ISSN:2379-3708
Container-title:JCI Insight
language:en
Short-container-title:

Author:

Prodeus Aaron,Abdul-Wahid Aws,Sparkes Amanda^ORCID,Fischer Nicholas W.,Cydzik Marzena,Chiang Nicholas,Alwash Mays,Ferzoco Alessandra,Vacaresse Nathalie,Julius Michael,Gorczysnki Reginald M.,Gariépy Jean

Publisher

American Society for Clinical Investigation

Subject

General Medicine

Link

https://insight.jci.org/articles/view/94308/files/pdf

Reference28 articles.

1. B7 family checkpoint regulators in immune regulation and disease

2. Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation

3. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial

4. The Emerging Role of CTLA-4 as an Immune Attenuator

5. Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. LRIG1 engages ligand VISTA and impairs tumor-specific CD8 ⁺ T cell responses;Science Immunology;2024-05-17

2. Repositioning baloxavir marboxil as VISTA agonist that ameliorates experimental asthma;Cell Biology and Toxicology;2024-02-10

3. Tackling of Immunorefractory Tumors by Targeting Alternative Immune Checkpoints;Cancers;2023-05-16

4. VISTA immune regulatory effects in bypassing cancer immunotherapy: Updated;Life Sciences;2022-12

5. VISTA as a ligand downregulates LPS-mediated inflammation in macrophages and neutrophils;Cellular Immunology;2022-09